iBstone AuraLink vs Lexie B3

The iBstone AuraLink is a mid-priced OTC hearing aid released in 2024, earning a B grade with a SoundScore of 3.6/5 in our lab testing. At $649, it ranks #33 of 65 OTC hearing aids tested, placing it in the top 49% of its category. This behind-the-ear device demonstrates a distinctive performance profile with notable strengths in specific areas. Music streaming stands out as a clear highlight, scoring 3.6/5—a solid result that lands 1.68 points above the OTC category average. Feedback handling is excellent at 5.0/5, exceeding the already-high category average by 0.46 points. Own-voice comfort scores 2.7/5, slightly above the category average but only mixed in absolute terms. The AuraLink's limitations appear in speech clarity metrics. Speech in quiet scores 2.3/5, falling 0.47 points below the category average—a mixed result that may affect conversational understanding in calm environments. Speech in noise presents a more significant challenge at 1.0/5, which is 0.48 points below the category average and low in absolute terms. This hearing aid may appeal most to users who prioritize music listening and phone streaming over speech clarity in challenging environments. However, budget-conscious shoppers should note that alternatives like the iHear MatriX offer higher scores at lower prices. The AuraLink's strength in feedback stability and streaming audio quality represents a specific value proposition for users whose priorities align with these capabilities.

The Lexie B3 is a mid-priced OTC hearing aid available at $999 that achieves an A grade with a SoundScore of 4.7/5 in our lab testing, ranking #1 among 65 OTC hearing aid devices tested. This behind-the-ear style device delivers category-leading performance across multiple metrics. Speech clarity is a standout strength. In our lab testing, the Lexie B3 scores an excellent 4.5/5 for speech in quiet, measuring 1.73 points above the OTC category average. Speech in noise performance scores 2.5/5—above the category average by 1.02 points, though only mixed in absolute terms at 2.5/5. This pattern reflects the broader challenge OTC devices face in noisy environments while still positioning the B3 as a top performer relative to its category. Music streaming quality is solid at 3.3/5, outperforming the category average by 1.38 points. Own-voice comfort scores a solid 3.0/5, sitting 0.49 points above average. Feedback handling is excellent at 4.6/5, essentially matching the already-strong category average. The Lexie B3 is best suited for consumers seeking top-tier OTC sound performance without prescription hearing aid costs. Those who prioritize speech clarity in quieter settings will find particular value here. Budget-conscious shoppers may want to consider alternatives like the RxEars Rxi, which offers strong performance at a lower price point.